LEAWOOD, Kan., Jan. 11, 2018 /PRNewswire/ -- Elanco Animal
Health, a division of Eli Lilly and Company (NYSE: LLY) and Aratana
Therapeutics, Inc. (NASDAQ: PETX), today announced the European
Commission adopted the decision to grant marketing authorization of
GALLIPRANT® (grapiprant tablets) in the European
Union.
Galliprant is a new veterinary medicine that will be indicated
for the treatment of pain associated with mild to moderate
osteoarthritis in dogs. Grapiprant, the active ingredient in
Galliprant, is a non-steroidal non-cyclooxygenase inhibiting
anti-inflammatory drug. Elanco has exclusive rights to develop,
manufacture, market and commercialize Galliprant globally, and it
co-promotes the product with Aratana in the United States.
About Elanco Animal Health
Elanco provides
comprehensive products and knowledge services to improve animal
health and food-animal production in more than 70 countries around
the world. We value innovation, both in scientific research and
daily operations, and strive to cultivate a collaborative work
environment for more than 6,500 employees worldwide. Together with
our customers, we are committed to raising awareness about global
food security, and celebrating and supporting the human-animal
bond. Founded in 1954, Elanco is a division of Eli Lilly and
Company. Our worldwide headquarters and research facilities are
located in Greenfield, Indiana
(U.S.). Visit us at www.elanco.com or
www.elancoeurope.com.
About Aratana Therapeutics
Aratana Therapeutics is a
pet therapeutics company focused on licensing, developing and
commercializing innovative therapeutics for dogs and cats. Aratana
believes that it can leverage the investment in the human
biopharmaceutical industry to bring therapeutics to dogs and cats
in a capital and time efficient manner. The company's pipeline
includes therapeutic candidates for the potential treatment of
pain, inappetence, viral diseases, allergy, cancer and other
serious medical conditions. Aratana believes the development and
commercialization of these therapeutics will permit veterinarians
and pet owners to manage pets' medical needs safely and
effectively, resulting in longer and improved quality of life for
pets. For more information, please visit www.aratana.com.
This press release contains forward-looking statements (as
that term is defined in the Private Securities Litigation Reform
Act of 1995) about the collaboration between Aratana and Elanco,
and reflects Lilly, Elanco's and Aratana's current beliefs.
However, as with any pharmaceutical product, there are substantial
risks and uncertainties in the process of development and
commercialization. Among other things, there can be no guarantee
that the research collaboration will yield successful results, that
either company will achieve the anticipated benefits or that the
results will be commercially successful. For further discussion of
these and other risks and uncertainties, see Lilly's and Aratana's
most recent Form 10-K and Form 10-Q filings with the United States
Securities and Exchange Commission, respectively. Except as
required by law, Elanco and Aratana undertakes no duty to update
forward-looking statements to reflect events after the date of this
release.
Media Contacts
Karin Gerbens
gerbens_karin@elanco.com
+32 476 978 467
Rachel Reiff
rreiff@aratana.com
+1 (913) 353-1050
View original content with
multimedia:http://www.prnewswire.com/news-releases/elanco-aratana-announce-marketing-authorization-of-galliprant-grapiprant-tablets-in-europe-300581366.html
SOURCE Aratana Therapeutics